U.S. markets closed

Dr. Reddy's Laboratories Limited (RDY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
59.97-0.64 (-1.06%)
At close: 4:00PM EST

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
India
91 40 4900 2900
http://www.drreddys.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees21,650

Key Executives

NameTitlePayExercisedYear Born
Mr. Gunupati Venkateswara Prasad B.E.Co-Chairman, MD & Member of Management CouncilN/AN/A1960
Mr. Kallam Satish ReddyChairman & Member of the Management CouncilN/AN/A1967
Mr. Erez Israeli M.B.A.CEO & Member of the Management CouncilN/AN/A1968
Mr. Deepak Sapra M.B.A.Sr. VP, Global Head PSAI Bus. & Member of Management CouncilN/AN/A1975
Mr. M. V. Ramana M.B.A., MBACEO of Branded Markets - India & Emerging Countries and Member of Management CouncilN/AN/A1969
Mr. Ganadhish KamatExec. VP, Global Head of Quality & Member of Management CouncilN/AN/A1963
Dr. Anil NamboodiripadSr. VP, Head of Proprietary Products, Head of Promius Pharma & Member of Management CouncilN/AN/A1967
Ms. Archana Bhaskar B.Sc., M.B.A.EVP, Head of Corp. Communications, Chief HR Officer & Member of Management CouncilN/AN/A1967
Mr. Sauri Gudlavalleti B.Tech.Sr. VP, Global Head of Integrated Product Devel. Organization & Member of Management CouncilN/AN/A1978
Mr. Yugandhar Puvvala M.B.A.Sr. VP, Global Head Global Supply Chain & Member of Management CouncilN/AN/A1971
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.

Corporate Governance

Dr. Reddy's Laboratories Limited’s ISS Governance QualityScore as of December 2, 2020 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.